A Flavonoid, Luteolin, Cripples HIV-1 by Abrogation of Tat Function

Rajeev Mehla¹, Shalmali Bivalkar-Mehla¹, Ashok Chauhan¹,²*

¹Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, South Carolina, United States of America
²Department of Pharmacology, Physiology and Neuroscience, University of South Carolina School of Medicine, Columbia, South Carolina, United States of America

Abstract

Despite the effectiveness of combination antiretroviral treatment (cART) against HIV-1, evidence indicates that residual infection persists in different cell types. Intensification of cART does not decrease the residual viral load or immune activation. cART restricts the synthesis of infectious virus but does not curtail HIV-1 transcription and translation from either the integrated or unintegrated viral genomes in infected cells. All treated patients with full viral suppression actually have low-level viremia. More than 60% of treated individuals also develop minor HIV-1-associated neurocognitive deficits (HAND) due to residual virus and immune activation. Thus, new therapeutic agents are needed to curtail HIV-1 transcription and residual virus. In this study, luteolin, a dietary supplement, profoundly reduced HIV-1 infection in reporter cells and primary lymphocytes. HIV-1 inhibition by luteolin was independent of viral entry, as shown by the fact that wild-type and VSV–pseudotyped HIV-1 infections were similarly inhibited. Luteolin was unable to inhibit viral reverse transcription. Luteolin had antiviral activity in a latent HIV-1 reactivation model and effectively ablated both clade-B- and -C-Tat-driven LTR transactivation in reporter assays but had no effect on Tat expression and its sub-cellular localization. We conclude that luteolin confers anti–HIV-1 activity at the Tat functional level. Given its biosafety profile and ability to cross the blood-brain barrier, luteolin may serve as a base flavonoid to develop potent anti–HIV-1 derivatives to complement cART.

Introduction

HIV-1 infection of the host cells proceeds with reverse transcription, viral DNA integration into the host genome, transcription, translation, proteolytic processing of viral proteins and subsequent assembly into nascent viral particles [1]. To a large extent, the introduction of combination antiretroviral treatment (cART) has curtailed viral replication below the detection limit (<50 copies/mL) and significantly reduced the devastating impact of HIV-1 [2–5]. cART works by blocking infection of susceptible new cells, while the decay rate of plasma virus is determined by the life span of previously infected cells [6]. However, given the presence of intact HIV-1 reservoirs, including quiescent CD4+ T lymphocytes, bone marrow and brain [7–8], as well as the development of viral escape mutants and drug resistance, viral replication goes unchecked by intensive therapy [9–14]. All treated patients with full viral suppression actually have low-level, steady-state viremia [10,15–16].

Given the long duration of treatment, virus develops drug resistance at multiple steps resulting in treatment failure. The HIV-1 transactivator of transcription (Tat) protein engages positive transcription elongation factor b (pTEFb) complex (cycT1 and CDK9), increasing RNA pol II activity and driving viral transcriptional elongation [17–19]. Tat activity is enhanced by host factors such as Tat-associated histone acetylases (TAH), p300/CBP, GCN5, and P/CAF, as well as P300/CBP and GCN5 acylate Tat at Lys 50 and 51 [20–23]. P/CAF acetylates Lys 28 on Tat and increases its ability to recruit pTEFb complex [20–22]. Thus, Tat is an important therapeutic target, having the ability to interrupt the viral life cycle. Coincidentally, no effective HIV-1 transcriptional inhibitor is yet available to complement cART. Thus, the alternative to keeping the virus in an under-expressed state until the infected cells have died is to inhibit HIV-1 transcription and subsequent viral protein synthesis, which requires new inhibitors.

Flavones, a class of flavonoids containing a characteristic 2-phenylchromene-4-one ring structure (Fig. 1a), are found in many herbs. They have shown therapeutic value, including antiviral and anti-inflammatory properties [24–27]. Luteolin (2-(3,4-Dihydroxyphenyl)- 5,7-dihydroxy-4-chromenone), myricetin, and quer cetin, which are structurally related flavones (Fig. 1a), act as anti-oxidants and free-radical scavengers, dramatically reducing inflammatory responses [24–25,28–32]. Their anti-oxidant property is related to the number and position of their hydroxyl groups [33]. Luteolin occurs in parsley, arichoke leaves, celery, peppers, olive oil, rosemary, lemons, peppermint, sage, and thyme; it acts as an anti-oxidant and anti-viral agent and is now being used in clinical trials for the inhibition of neuro-inflammation [24,29]. Luteolin also has been found to have anti-HIV-1 activity [31,34]. Although luteolin is a promoter of carbohydrate metabolism and an immune system modulator, it has been shown to have potent anti-inflammatory activity by inhibiting nuclear factor kappa B (NF-κB) in macrophages and other immune cells [35–36].
In addition, luteolin was shown to be effective against SARS coronavirus in a study using recombinant HIV-1 pseudotyped with SARS CoV envelope [27]. Another study found HIV-1 protease inhibitor activity in cell-free assays, but this has not been validated in infection studies. Moreover, the precise mechanism of HIV-1 inhibition is unclear [34]. Flavonoids (quercetin, myricetin and luteolin) are structurally closely related; they are being used as dietary supplements in the United States. They have also been investigated for their anti-HIV-1 activity and its possible mechanism of action. Although we found that these three flavonoids are nontoxic and have anti-HIV-1 activity. Luteolin was the most potent and inhibited HIV-1 infection by abrogating Tat-mediated LTR activity.

Results and Discussion

Given the long-term persistence of intact HIV-1 reservoirs, along with the development of viral escape mutants and drug resistance, viral replication goes unchecked even by intensive therapy [9–14,37]. Uninterrupted lifelong anti-HIV-1 treatment has resulted in longer survival but, with the persistence of residual viral activity and immune activation [37], more than 60% of cART-treated individuals develop minor cognitive disorders [38]. In addition, anti-HIV treatment leads to immune reconstitution inflammatory syndrome (IRIS) in a substantial number of African patients [39–40]. Above all, development of drug resistance by HIV-1 is commonly encountered during long-term treatment. Thus, a continuing search for new therapeutic agents to target novel viral life cycle stages is needed.

The use of naturally occurring compounds such as a dietary supplement having anti-HIV-1 and anti-oxidant properties potentially provides an attractive therapy in combination with cART. We have investigated the ability of flavonoid compounds (Fig. 1A) to alter HIV-1 activity in screening assays using LTR-luciferase (TZM-bl) reporter cells and primary lymphocytes as infection models. TZM-bl cells are HeLa cells that stably express CD4 and CXCR4 receptors. They contain an integrated copy of the HIV-1 long terminal repeat (LTR) fused with luciferase and beta galactosidase genes [41]. Expression of the indicator luciferase gene is under the control of LTR via transactivator Tat protein, which is synthesized by either the viral infection or the plasmid expression vector. TZM-bl cells were treated for 30 min with luteolin, quercetin, or myricetin at 5 and 10 μM concentrations before HIV-1 infection. Forty-eight hours later, the infected reporter cells were monitored for LTR activity using luciferase reporter assay. Intriguingly, all of the flavonoid compounds at 5 and 10 μM concentrations showed anti-HIV-1 activity, but luteolin was the most potent (Fig. 1B). HIV-1 inhibition by luteolin was specific, as vehicle control (DMSO) had no effect on LTR activity. To rule out interference by toxicity, we monitored cell viability after flavonoid treatments, using the WST8 cell–viability assay [42] on TZM-bl cells. None of the compounds showed any cellular cytotoxicity at 10 μM concentrations (Fig. 1C). Although, luteolin showed slight toxicity in TZM-
bl reporter cells, it was found, on verification on Hela and Jurkat cells (Fig. 2A) and lymphocytes, to be relatively nontoxic. The toxicity of luteolin in TZM-bl cells could result from the presence of multiple stable constructs in these cells. Moreover, earlier studies on several cell systems have reported that luteolin in concentrations up to 100 μM [43] had no adverse effects. Our data suggest that the flavonoids actively inhibited HIV-1 activity, possibly through malfunctioning of Tat activity. This could be due to blockage at any step in the viral life cycle.

In further studies, we examined the anti-HIV-1 activity of luteolin in greater detail. We tested different concentrations of luteolin (0–40 μM) on cell viability in different cell models to find a workable nontoxic concentration. Luteolin in concentrations between 5 and 10 μM, the upper limit for therapeutic agents used in screening assays, had significant antiviral activity. Thus, we used luteolin at 5 and 10 μM for all experiments (Fig. 2). We confirmed the anti-HIV-1 activity of luteolin in infection assays in lymphocytic cells and primary human lymphocytes using either wild-type (NLENG1) or VSV-pseudotyped HIV-1. In infection studies, we used HIV-1 NLENG1 containing GFP gene cloned between the envelope and nef region [44,45]. Thus, we could monitor productive viral gene expression not only by GFP expression, using fluorescence microscopy, but by HIV-1 p24 capsid protein in the supernatants, which was detected by ELISA [42,44].

![Graphs showing cell viability and HIV-1 infection](image)

**Figure 2.** Luteolin inhibited HIV-1 infection in Jurkat cells. A. Viability of TZM-bl, Hela, and Jurkat cells after treatment with different concentrations of luteolin (0–40 μM) for 24–48 h as determined by WST8 assay (n = 3). B–D. Jurkat cells were pretreated for 30 min with 5 μM or 10 μM luteolin (LN5 and LN10, respectively), vehicle (DMSO), or AZT (positive control) followed by HIV-1 infection for 2 h at 37°C. HIV-1 infection was monitored by (C) GFP expression or (D) virus release in supernatants as determined by p24 ELISA on the 5th day post-infection. GFP quantification was done by counting 10 random low-power fields and plotted as mean ± SEM (n = 2).

doi:10.1371/journal.pone.0027915.g002
Jurkat cells were pretreated with luteolin or vehicle (DMSO) for 30 min followed by HIV-1 infection, as reported earlier [42]. After infection, luteolin treatments were maintained for 3–5 days, the duration of the experiment. Luteolin treatment markedly reduced the HIV-1 infection in Jurkat cells (Fig. 2B–D) in a dose-dependent manner as shown by reductions in both the number of GFP-positive cells and viral p24 release in the supernatants on the fifth day after infection. To confirm these above findings and also rule out the cell-specific inhibition of HIV-1, we infected TZM-bl cells and obtained similar suppression of viral infection (Fig. 3A–D). Although treatment with luteolin prior to HIV-1 infection had no additional advantage on virus replication as compared with overnight treatment after HIV-1 infection (Fig. 3C, D). Instead better HIV-1 inhibition was seen with the latter, indicating that luteolin may affect the later stages of the HIV-1 life cycle rather than restricting the virus at the receptor, reverse transcription or viral DNA integration steps.

To test this possibility, we did infection studies on primary human lymphocytes using wild type virus and additionally VSV-NLNLG1 (HIV-1) was used to facilitate rapid and homogeneous receptor-independent viral infection. Before these studies, we confirmed that luteolin was non-toxic to primary cells (Fig. 4A).

We treated wild-type and VSV-HIV-1 infected lymphocytes with 5 and 10 μM of luteolin until follow-up and monitored for viral infection by GFP expression and the release of p24 in culture supernatants (Fig. 4B–D). Luteolin treatment alleviated HIV-1 infection (wild-type or VSV-HIV) as shown by a reduction in GFP expression (Fig. 4B) and p24 levels in the supernatants following virus release at 2, 4, and 6 days after infection (Fig. 4C, D). In parallel, 5, 6- dichloro- 1-b -D-ribofuranosyl-1H-benzimidazole (DRB), a transcriptional inhibitor (RNA pol II inhibitor) was used as a positive control, while vehicle (DMSO) was used as a solvent control. DRB suppresses HIV-1 transcription by inhibiting RNA polymerase activity [46–47]. Interestingly, luteolin treatment of HIV-1 infected lymphocytes also showed inhibition in cell aggregation/syncytia similar to that produced by DRB and cell control (Fig. 4B), suggesting that viral envelope (gp120) protein expression on cell surfaces is impaired. Viral gp120 expression on infected cells is required for syncytia formation or aggregation of cells. In addition, luteolin did not affect the proliferation of lymphocytes during viral inhibition studies.

Our results thus far indicated that the mechanism of luteolin-mediated HIV-1 suppression is independent of viral entry receptors. To corroborate the effect of luteolin on wild-type virus, TZM-bl reporter cells were pretreated with luteolin or DMSO for 30 min, then infected with HIV-1 (p24 = 250 ng/ml). We assessed the effect of luteolin on virus entry after 6 h of infection by the accumulation of intracellular viral capsid (p24), which was quantified by ELISA in HIV-1—infected cell lysates. As a positive control for entry inhibition, we pretreated TZM-bl cells with a CXCR4 blocker, AMD 3100, before infecting them with HIV-1. Luteolin (5–10 μM) pretreatment did not have a significant effect on wild-type HIV-1 entry as compared to that in untreated infected cultures (Fig. 5A). To rule out the possibility of contamination from cell-membrane-bound virus particles in the cell lysates, we tested p24 levels in HIV-1-infected cell supernatants (HIV-sup) at 6 h after infection and found barely detectable levels (Fig. 5A).

The preceding results showed that luteolin inhibited HIV-1 infection independent of viral entry. We then investigated whether luteolin had any effect on viral reverse transcription. After infecting TZM-bl cells with HIV-1 for 2 h and treating them with luteolin, we monitored the levels of reverse-transcribed intracellular HIV-1 DNA at 6 h after infection, using real-time PCR [48]. In this situation, unlike that when we used AZT, a reverse transcriptase inhibitor (positive control), treating HIV-1 infected TZM-bl cells with luteolin did not significantly alter the amount of reverse transcribed HIV-1 DNA (Fig. 5B). This suggested that luteolin was unable to annihilate viral reverse transcription.

We then investigated the effect of luteolin on viral integration, first testing viral integration kinetics in VSV-pseudotyped HIV-1-infected Jurkat cells from 0 to 24 h using semiquantitative Alu-integration PCR, with GAPDH as an internal control [44]. The minimum PCR amplification cycles were optimized to obtain the amplification product in linear log phase. Densitometric analysis of amplified PCR products showed that viral integration was rapid in Jurkat cells, starting within just 4 h after infection (Fig. 5C). This is consistent with earlier findings on VSV-HIV-1 [49]. However, our results suggest that the peak integration levels are reached by 8–10 h after infection, slightly longer than in an earlier study [49]. These differences could be due to use of different HIV-1 strain in the above study.

To test the effect of luteolin on viral integration, we infected Jurkat cells with VSV-pseudotyped HIV-1, then treated the cells with either luteolin or vehicle at times ranging from 4 to 12 h. After 24 h, viral infection was monitored by GFP expression and viral integration, using Alu-LTR PCR as described (Fig. 5D, E). In parallel, we used integrase-defective mutant HIV-1 (D64A) as a control [50,51]. As compared to vehicle controls, luteolin-mediated suppression of HIV-1 expression was evident irrespective of the time after infection when treatment was initiated (4–12 h) (Fig. 5D). The weak suppression in integration signal as compared to that in untreated infected cells (Fig. 5E) was in contrast to a previous report showing exclusive effect on viral integration [51].

**Figure 3. Luteolin inhibited HIV-1 infection in TZM-bl reporter cells.** TZM-bl cells were pretreated for 30 min with 0, 5, and 10 μM luteolin, then infected with HIV-1 for 2 h at 37°C. HIV infection was monitored by (A) GFP expression or (B) virus released in supernatants as determined by p24 ELISA on 3rd day post-infection (n = 3). C, D. TZM-bl cells were pre- or post-treated with luteolin (10 μM) followed by HIV-1 infection. (C) At 72 h post-infection, HIV-1 infection was monitored by GFP expression. (D) Culture supernatants were analyzed for the virus p24 antigen by ELISA. (n = 2).

doi:10.1371/journal.pone.0027915.g003
Intriguingly, the suppression of HIV-1 infection in cells treated with luteolin at 12 h post-infection suggests that luteolin has an inhibitory effect on the HIV-1 life cycle mainly if not exclusively at the postintegration stage.

Given that integration was already complete within 8–10 h post-infection (Fig. 5C), we further explored the effect of luteolin on post-integration steps of the HIV-1 life cycle. To investigate HIV-1 replication independent of viral DNA integration, we transfected TZM-bl cells with HIV-1 DNA expression vector. After treating the cells with luteolin or vehicle control (DMSO), we monitored viral gene expression using the LTR-luciferase assay. In this system, Tat expression from HIV-1 DNA drives LTR-luciferase expression, which was quantified luminometrically. Luteolin treatment markedly inhibited HIV-1 gene expression (or at least Tat expression) as compared to that in control TZM-bl reporter cells (Fig. 6A). Given that HIV-1 plasmid DNA expression vector replicates independently of viral DNA integration, it is evident that luteolin inhibited either Tat expression or Tat function at the LTR level, but not HIV-1 DNA integration.

To validate the HIV-1 plasmid DNA expression results, we did infection studies in which VSV-pseudotyped HIV-1 wild-type viruses or envelope-deficient HIV-1 viruses were used on TZM-bl reporter cells. As compared to controls, luteolin-treated VSV-HIV-1-infected reporter cells profoundly suppressed the Tat-regulated luciferase signal similar to that in HIV-1 plasmid DNA transfection (Fig. 6A), suggesting aborted viral replication. DMSO controls also showed some suppression in luciferase signal in both HIV-1 DNA transfected and VSV-virus infected TZM-bl cells. One possibility is that DMSO affects luciferase expression either at the mRNA level or via CMV promoter. However, we confirmed our HIV-1 inhibition results on Magi cells (CD4/CCR5+ve HeLa cells) using GFP and viral p24 as markers. We transfected these cells with recombinant HIV-1 plasmid DNA vector expressing GFP [NLENG1], then treated them with luteolin for 12–24 h. At 48 h after transfection, we monitored GFP expression and viral p24 antigen in the supernatants, finding that luteolin treatment suppressed both (Fig. 6B, C), which suggested inhibition at the post-HIV-1 DNA integration step. We are convinced that small inhibition in DMSO-treated VSV-HIV-1 infected cultures or
HIV-1 DNA transfected reporter cells was made possible by the effect on viral (VSV) endocytosis. However, we do not underestimate the true effect of luteolin, which was corroborated by inhibition of wild-type infection, HIV-1 DNA-mediated LTR transactivation, and post-integration viral state without any inhibitory effect of DMSO. Antiviral activity of luteolin is clearly shown in wild–type HIV-1 infection studies wherein DMSO did not confer any antiviral activity. These results ruled out any additive effect of DMSO with luteolin on HIV inhibition.

Thus far, luteolin-mediated suppression of the LTR-luciferase activity has been demonstrated after HIV-1 plasmid DNA transfection or HIV-1 infection, suggesting that luteolin may confer anti-viral activity at the functional level of Tat-LTR function, Tat expression and its sub-cellular localization or downstream viral protease. To further examine luteolin-mediated inhibition of HIV-1 at post-DNA integration stages, we did experiments on latently HIV-1 infected THP89 cells, in which the HIV-1 genome contains the GFP gene. THP89 cells contain HIV-1 provirus in a latent state without any viral gene expression including GFP [44]. On induction by TNF-a (NF-kB activation) or Trichostatin A (histone deacetylase inhibitor), however, viral reactivation is initiated; cells start expressing GFP and release the virus extracellularly [32,45,48]. After THP89 cells had been pretreated with luteolin or DMSO for 18 h, viral reactivation was initiated using TNF-a (10 ng/ml). TNF-a-reactivated latent HIV-1 infection was attenuated by treatment with luteolin (10 μM), demonstrating reduction in GFP expression and released virus (p24) in 24, 48, and 72–h induction periods (Fig. 7A–B).
indicates that luteolin has an effect on post-viral DNA integration stages; that is viral transcription or translation or Tat functional activity. When Tat functional activity is impaired in a TNF-α — reactivated latent HIV-1 model, GFP expression, including viral proteins that are dependent on Tat function, will eventually be impaired, so that p24 activity is reduced in infected culture supernatants.

Taken together, our multiple lines of evidences indicated that luteolin confers its anti-HIV-1 activity by inhibiting HIV-1 transcription, translation, or post-translational processing (protease). However, given our finding that GFP expression was reduced in both TNF-α reactivated latent HIV-1 infection and acute viral infection; the data point toward transcriptional inhibition or translation (Figs. 2, 3, 4, 5, 6, and 7), which was not expected from crippled viral protease, GFP is cloned between env and nef genes in both TNF-α and Tat sub-cellular (nuclear/nucleolar) localization was unaffected by luteolin, as in DMSO- or mock- treated cells (Fig. 8D). In parallel, transcriptionally inactive Tat-47 mutant (Δ48–56) deleted in nuclear localization signal was used as negative control, demonstrating only basal luciferase activity in both Tat-47- and empty vector (pcDNA)- transfected TBM-bl cells.

Given that Tat is a bona fide nuclear/nucleolar protein, we further investigated whether luteolin affects Tat expression independently of viral DNA integration. A TBM-bl reporter cells in 12 well culture plates were transfected with HIV-1 plasmid DNA vector expressing GFP, then treated with luteolin (10 μM) or DMSO (Veh). In parallel, TBM-bl cells were infected with VSV-HIV NLNEG1 or NLR+E for 2 h, then treated with luteolin (10 μM) or DMSO for the duration of follow up. At 48 h post-transfection or infection, cells were lysed and assayed for luciferase activity (n=2). B–C. Two hours after Magi cells were transfected with pHIV NLNEG1 (150 ng), luteolin (10 μM) was added to them. After 6 h, transfection medium was replaced with fresh medium containing luteolin for 12 or 24 h. At 48 h post-transfection, cells were monitored for GFP expression. Representative pictures are shown (B). Cell supernatants were collected to measure p24 levels (C) (n=2). *** p<0.001, ### p<0.005.

These observations confirm that luteolin confers its anti-HIV-1 activity at the Tat-LTR transcription level (transcription step) after the viral integration step. However, further investigations of the action of luteolin are needed to decipher the detailed mechanism of Tat-mediated LTR inhibition. Currently, we are investigating the interactions of Tat with HIV-1 LTR and host transcription factors, as well as post-translational modification on Tat in the presence of luteolin. Several compounds, such as Quinolines, as well as stibene- and pyrrole-derivatives have been
reported to show anti-HIV activity, inhibiting Tat-TAR interactions [60–64]. Other compounds, such as flavipiridol, rescovtine, and 9-amino acridine, targeted CDK9, a component of pTEFb complex [65–67]. Recently, a coumarin derivative has been shown to potently inhibit HIV Tat function in nano-molar concentrations by repressing p300 and PI3K/AKT [68]. This supports the

Figure 7. Luteolin inhibited reactivation of latent HIV-1 infection. (A, B) One million latently HIV-infected THP89 cells seeded per well in 12 well culture plates were pretreated overnight with luteolin (5 or 10 μM) or DMSO, then stimulated with TNF-α (10 ng/ml) and monitored by (A) GFP expression and (B) virus production by p24 ELISA. Similarly, 10 μM luteolin treatments were given from 12 h to 72 h post -TNF-α stimulation. Virus production was monitored by p24 ELISA. DRB (10 μM) was used in parallel as a positive control (n = 3). (C) Luteolin inhibited transactivation of integrated HIV-LTR. SVGA-LTR-GFP reporter cells were transduced with VSV-Tat viral particles for 2 h, then treated with 10 μM luteolin or vehicle and, after 24 h, monitored for GFP expression.

doi:10.1371/journal.pone.0027915.g007
possibility that luteolin leads to the development of potent derivatives to inhibit HIV in nano–molar concentrations. Therefore, several other active derivatives of luteolin shown to have more potent antioxidant and anti-inflammatory properties need to be investigated for anti-HIV-1 activity. Intriguingly, quercetin, a luteolin analogue, has been shown to repress proinflammatory miRNA-155 in macrophages in –vivo [43], it would be interesting to determine whether luteolin has the same effect. One caveat is that luteolin may complement combination anti-HIV therapy by preventing synthesis of viral proteins available for protease steps. This would enhance the potency of protease inhibitors, eventually leading to reduced virus assembly and release.

In conclusion, our results on reporter cells and primary lymphocytes indicate that luteolin cripples HIV-1 Tat function and may be the critical component in anti-retroviral combination therapy for HIV-1 infection. In addition, luteolin crosses the blood-brain barrier and has been shown to confer neuroprotective effects via inhibition of neuroinflammation [28,69–71]. However, the concentrations of luteolin that we found to be inhibitory in our study are in the upper therapeutic ranges. Further investigation is needed to determine whether these concentrations are achieved in vivo. Further investigations in–vivo and significance of luteolin with anti-HIV drugs whether it can act in synergism with lower concentrations, are the future goals. However, we have laid the foundation for development of luteolin derivatives that, in nanomolar ranges, may which could inhibit HIV-1. Currently, we are investigating the ability of 500 flavonoid derivatives to inhibit HIV in nano molar ranges.

**Materials and Methods**

Primary cells, cell lines, and reagents

Human peripheral blood mononuclear cells (PBMCs) were separated from whole blood (New York blood bank) using Histopaque (Sigma, St., MO), washed three times with phos-
confirmed by double-strand DNA sequencing. The HIV-1 long pcDNA3.0 vector at EcoRI and XhoI sites. The inserts were signal (amino acids 47–56) and was cloned with HA tag in subtype B mutant was created by deletion of nuclear localization promoter and packaged with a VSV envelope as described earlier [50]. Full-length subtype B Tat [73], and VSV-G expression plasmids [74] through the National AIDS Reagent and Reference Program, NIH. TZM-bl, SVGA-LTR-GFP reporter cells. HIV-1 full length DNAs or lentiviral vector pLVX expressing Tat were packaged in 293T cells as described previously [42]. Briefly, we transfected 17 μg of HIV or lentiviral expression vector DNA per 100 mm culture dish (BD Falcon) using Lipofectamine 2000 (Invitrogen). Similarly, we pseudotyped HIV-1 NLNEG1 or HIV-1 pNL4-3.HSA.R5.E proviral DNA (17 μg) with VSV-G envelope using a 4.0 μg VSV-G construct. To pseudotype lentiviral vector, cells were transfected with 10.0 μg pLVX-Tat or pLVX with 3.0 μg pCMV-Tat, 8.0 μg pGag-Pol, 4.0 μg pCMV-Rev, 2.5 μg pVpr, and 4.0 μg pVSV-G using Lipofectamine 2000 [42]. The supernatants containing viral particles were harvested 72 h after transfection and centrifuged at 300 g for 10 min to remove cellular debris. Further, viral stocks were treated with 5 IU/ml of RNase-free DNase for 15 min at room temperature and membrane-filtered. Stocks were filtered and stored as 1.0 ml aliquots at −80°C. Viral titers were determined by p24 ELISA (Zetaplextrix, Buffalo, NY) or by transducing SVGA-LTR-GFP reporter cells.

**Western blotting and immunofluorescence**

TZM-bl cells were transfected with pIRES2-EGFP-Tat-HA and, on the next day, treated them with luteolin or DMSO. Cells were harvested 48 h after transfection and lysed in RIPA buffer (Sigma) containing a protease inhibitor cocktail (Pierce); 30 μg of total protein from each sample was then analyzed on 12% SDS-PAGE. Protein bands were transferred to polyvinylidene difluoride (PVDF) membranes (BioRad) [48]. We blocked the membranes with blocking buffer (5% nonfat dry milk, 0.1% Tween 20 in PBS) for 1 h at room temperature. Overnight, the membranes were probed at 4°C with rabbit polyclonal antibody against HA peptide (1:1000, Santa Cruz Biotechnology) and, as an internal control, mouse monoclonal antibody against beta actin (1:3000 dilution, Sigma). After three washes with 0.1% Tween 20 in PBS, the membranes were incubated with anti-rabbit IgG secondary antibody conjugated to horseradish peroxidase (1:3000, BioRad) in blocking buffer for 1 h at room temperature. We washed the membranes three times with 0.1% Tween 20 in PBS and developed them using a chemiluminescence detection kit ECL (GE Healthcare). Tat levels were quantified by densitometric analysis using ImageJ software (NIH). Normalization of samples was done at two levels using equal protein concentrations for loading followed by actin levels.

**Figure 9. Proposed schematic representation of anti-HIV activity of luteolin.** After HIV-1 DNA integration into host genome, viral genes are expressed under the control of the HIV-1 long terminal repeat (LTR) as a promoter with the help of viral regulatory protein Tat, which binds with TAR RNA element in the 5' end of LTR. Luteolin may abrogate Tat-mediated LTR transactivation activity by interfering with pTEF-b binding with LTR or abolish Tat binding; it also may prevent NF-kB activation or inhibition of host factors involved in transcription or inhibition of viral mRNA translation.
doi:10.1371/journal.pone.0027915.g009

phosphate-buffered saline (PBS), and cultured in 10% FBS containing RPMI as previously described [42]. TZM-bl (CD4/CXCR4/CCR5+ve HeLa cells) and Jurkat cells were obtained through AIDS Reagent and Reference Program, NIH. TZM-bl, SVGA-LTR-GFP cells [52] were grown in DMEM while Jurkat cells were grown in RPMI with 2 mM L-glutamine and RPMI (Gibco-BRL), each supplemented with 10% FBS, 1% penicillin, streptomycin, and amphotericin B (GibcoBRL). We obtained all chemical reagents from Sigma (St. Louis, MO). Stocks for luteolin, quercetin, and myricetin were prepared in dimethyl sulphoxide (DMSO). All flavonoids used in the study were of more than 98% purity. Rabbit polyclonal anti-HA antibodies were purchased from Santa Cruz Biotechnology, mouse anti-B23 (nucleophosmin) antibody from Abcam, Alexa 568 conjugated goat anti-rabbit IgG, and Alexa 488 conjugated goat anti-mouse IgG from Invitrogen. We purchased mouse monoclonal anti-beta-actin antibody from Sigma.
Immunofluorescence staining was done as described previously [44]. HeLa cells seeded in slide flasksets (Nunc, Denmark) were transfected with 500 ng of pDNA-Tat-HA expression vector using Lipofectamine 2000. At 24 h after transfection, cells were fixed with 2% paraformaldehyde for 15 min at 25 °C. The cells were washed twice with PBS and permeabilized by Triton X-100 (0.2%; v/v) in PBS for 11 min. Slides were overlaid with primary antibodies against HA (rabbit) and B23/nucleophosmin (monoclonal) as a nuclear maker, and each antibody diluted to 1:500. Slides were kept overnight at 4 °C. In parallel, IgG1 antibody was used as an isotype antibody control. The slides were washed three times with PBS and overlaid with alexa-568 conjugated goat-anti-rabbit (1:500) and alexa-488 conjugated goat-anti-mouse (1:500), then incubated at 25°C for 35 min. After two washings, nuclei were stained using Hoechst (1 μg/ml) for 5 min. Slides were mounted in fluoromount (Sigma), an aqueous gel mounting medium. Slides were examined with Nikon E600 fluorescence microscope and images acquired at 20× magnification.

**HIV-LTR reporter assay**

We infected TZM-bl cells with HIV-1 (p24 = 250 ng/ml) or transfected them with Tat expression vector using Lipofectamine 2000 (Invitrogen) [53] either in 96-well or 12-well plates, then treated the cells with luteolin or vehicle control. The DNA concentrations in transfection were normalized using empty control vector (pcDNA). At 48 h after treatment, we lysed cells using reporter lysis buffer (Promega), then put them through one freezing-thawing cycle. 30 μl of cell lysates was used to monitor luciferase activity in a 100-μl reaction using ready-glow firefly luciferase substrate (Promega). We quantified the luminescence in optilux black plates (Falcon) using a multi-mode microplate reader (BioTek instruments).

To detect viral DNA synthesis after reverse transcription in HIV-1 infection studies, we did real-time PCR as described earlier [48]. Briefly, we harvested DNA from the infected cells using DNAzol (Invitrogen) [48]. The cells were removed by trypsinization and washed twice with PBS, after which we added 1.0 ml DNAzol to cell pellets. DNA was precipitated by adding 500 μl of cell lysate was used to monitor luciferase activity in a 100-μl reaction using ready-glow firefly luciferase substrate (Promega). We quantified the luminescence in optilux black plates (Falcon) using a multi-mode microplate reader (BioTeck instruments), then calculated the percent of LTR luciferase activity as relative luciferase units normalized to cell control.

**Real-time PCR and Alu-HIV-1 integration PCR**

To detect viral DNA synthesis after reverse transcription in HIV-1 infection studies, we did real-time PCR as described earlier [48]. Briefly, we harvested DNA from the infected cells using DNAzol (Invitrogen) [48]. The cells were removed by trypsinization and washed twice with PBS, after which we added 1.0 ml DNAzol to cell pellets. DNA was precipitated by adding 500 μl of cell lysate was used to monitor luciferase activity in a 100-μl reaction using ready-glow firefly luciferase substrate (Promega). We quantified the luminescence in optilux black plates (Falcon) using a multi-mode microplate reader (BioTeck instruments), then calculated the percent of LTR luciferase activity as relative luciferase units normalized to cell control.

The following primer sets were used: Tat forward: 5'-GAAGCATCCAGGAAGTCAGCC-3' Tat reverse: 5'-GTGCTCAGTGTAGCCCAGGATG-3' GAPDH forward: 5'-CATCAGGAATGCTCTGACCG-3' GAPDH reverse: 5'-GTGCTCAGTGTAGCCCAGGATG-3'.

**Cytotoxicity assay**

TZM-bl or HeLa cells were seeded in 96-well plates at a density of 2.5×10^4. Jurkat cells were seeded at a density of 5.0×10^4 per well. We cultured the cells overnight and, next day, treated the cells with luteolin or control in triplicate. After 24 or 48 h, we measured the viability of cells after removing the culture medium and adding 100 μl PBS containing 10 μl of cell counting kit-8 (CCK-8) reagent (Dojindo Molecular Technologies, MD). After 3 h of incubation at 37°C, we collected the supernatants and measured the absorbance at 450 nm wavelength on a multi-mode microplate reader (BioTek instruments, VT) [42]. The percent of viability was calculated as (OD_{test}/OD_{cell control})×100. For human PBMCs, MTT assay was done by adding 20 μl of MTT reagent (Sigma) from 5 mg/ml stock prepared in PBS. The cells were incubated with MTT reagent for 3 h, after which 100 μl of isopropanol was added to dissolve formazan crystals. Absorbance was monitored at 570 nm wavelength on a microplate reader (BioTeck instruments).

**Statistics**

The results were presented as mean ± SEM for each bar graph plotted using Sigma plot v8.0 with associated p values for each treatment group compared to its controls. Statistical analysis was done using Origin 6.1 software. The significance between two groups was calculated using a two-tailed student’s t-test followed by one-way analysis of variance. P<0.05 was considered to be significant.

**Acknowledgments**

We thank Dr. Xin Zhao, a post doctoral fellow, for her contributions; Dr. David N. Levy (NYU, NY) for HIV-1 NLENG1 genomic DNA and THP19 cells; and Dr. Bruno Canque (INSERM, France) for NL4-3D64A proviral DNA. The following reagents were obtained through the National Institutes of Health (NIH) AIDS Research and Reference Reagent Program.
Program, Division of AIDS, NIAID; pNL-3.HSA+R+E, from Dr. Nathaniel Landau (NYU); TZM-bl from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc.; clade C Tat from Dr.Uday Kumar Ranga [JNC for Advanced Scientific Research, India]; and VSV-G expression vector from Dr. Lung-Ji Chang. Peripheral blood mononuclear cells (PBMCs) were obtained from New York Blood Bank (IRB exempt). All cell cultures (primary human and cell lines), HIV infection, and HIV-1 plasmid DNA studies were done according to university guidelines in a biocountainment facility approved by the Institutional Biosafety Committee (IBC) of the University of South Carolina.

Author Contributions
Conceived and designed the experiments: AC RM. Performed the experiments: RM SB. Analyzed the data: AC RM. Contributed reagents/materials/analysis tools: AC RM SBM. Wrote the paper: AC RM.

References
1. Greene WC, Peterlin B (2002) Charting HIV’s remarkable voyage through the complexities of nature: a passport to future therapy. Nat Med 8: 673–680.
2. Chun TW, Engel D, Mizell SB, Hallahan C, Fischette M, et al. (1999) Effect of interleukin-2 on the pool of latently infected, resting CD+ T cells in HIV-1-infected patients receiving highly active antiretroviral therapy. Nat Med 5: 734–739.
3. Guikema RM, Mellors JW, Hadix D, Eron JJ, Gonzalez C, et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337: 835–840.
4. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, et al. (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trial Group 320 Study Team. N Engl J Med 337: 725–733.
5. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853–860.
6. Spivak AM, Rahb SA, McMahon MA, Shan L, Sedaghat AR, et al. (2011) Dynamic Constraints on the Second Phase Compartment of HIV-Infected Cells. Cell 145(2): 252–265.
7. Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, et al. (2006) Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in coexisting CD4+ T cells. J Virol 80: 6441–6453.
8. Bukinsky MJ, Stanwick TL, Dempsey MP, Stevenson M (1991) Quercetin T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254: 423–427.
9. Bower ET, Schon A, Freire E (2010) Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors. Biochemistry 49: 2359–2367.
10. Palmer S, Maldarelli F, Wieand A, Bernstein B, Hanna GJ, et al. (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 105: 3079–3084.
11. Shafer RW, Schapiro JM (2008) HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 10: 67–84.
12. Shahriar R, Rhee SY, Liu TF, Fessel WJ, Scarsella A, et al. (2009) Nonpolyhedral human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations. Antimicrob Agents Chemother 53(9): 4069–4078.
13. Tilton JC, Amrine-Madsen H, Miamidian JL, Kirinos KM, Piff JF, et al. (2010) HIV-1 protease type 1 from a patient with baseline antiretroviral resistance reseeds drug-resistant escape mutants. Clin Infect Dis 47: 102–104.
14. Hatanou H, Delsart EL, Norris R, Lee TH, Neihius TB, et al. (2010) Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS 24: 2353–2359.
15. Garber ME, Wei P, Ramaratnam MV, Mayall TP, Herrmann CH, et al. (1998) The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CcylT1 protein. Genes Dev 12: 3512–3527.
16. Karr J (1999) Tackling Tat. J Mol Biol 291: 235–254.
17. Zhu Y, Pevery T, Peng J, Ramanathan Y, Marshall N, et al. (1997) Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev 12: 3512–3527.
18. Yi L, Li Z, Yuan K, Qiu X, Chen J, et al. (2004) Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J Virol 78: 11334–11339.
19. Chen HQ, Jin ZY, Wang XJ, Xu XM, Deng L, Zhao JW (2008) Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation. Neurosci Lett 448: 175–179.
20. Gates MA, Tworoger SS, Hecht JL, De V, Rosen JB, Hankinson SE (2007) A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer among black women. Int J Cancer 121: 2225–2232.
21. Hempel J, Pforte H, Raab B, Engst W, Bohm H, Jacobshahn G (1999) Flavonoids and flavones of parsley cell suspension culture change the antioxidative capacity of plasma in rations. Nahrung 43: 201–204.
22. Skalak S, Miyahiro H, Nakamura N, Hattori M, Kawahata T, et al. (2003) HIV-1 integrase inhibitory substances from Coleus parvifolius. Phytother Res 17: 232–239.
23. Yoo DR, Jiang YH, Jeon YK, Kim KY, Jeon W, et al. (2009) Proteomic identification of anti-cancer proteins in luteolin-treated human hepatoma HuH-7 cells. Cancer Lett 282: 49–54.
24. Noroozi M, Angerson WJ, Lean ME (1998) Effects of flavonoids and vitamin C on oxidative DNA damage to human lymphocytes. Am J Clin Nutr 67: 1210–1218.
25. Xu JX, Wan M, Dong H, Bu PP, Foy LY (2000) Inhibitory activity of flavonoids and tannins against HIV-1 protease. Biol Pharm Bull 23: 1072–1076.
26. Chen CY, Peng WH, Tsai KD, Hsueh SL (2007) Luteolin suppresses inflammation-associated gene expression by blocking NF-kappaB and AP-1 activation pathway in mouse alveolar macrophage. Life Sci 81: 1602–1614.
27. Chui E, Lee YS (2010) Luteolin suppresses IL-1beta-induced cytokines and MMPs production via p38 MAPK, JNK, NF-kappaB and AP-1 activation in human synovial sarcoma cell line, SW082. Food Chem Toxicol 48: 257–261.
28. Chua TM, Murray DJ, Justement JS, Hallahan CW, Miori S, et al. (2011) Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 204(1): 135–140.
29. Osduner H (2003) Molecular mechanisms of HIV-1 associated neurodegeneration. J Biosci 30: 391–405.
30. Letang E, Miro JM, Nhampossa T, Ayala E, Gascon J, et al. (2011) Incidence and predictors of immune reconstitution inflammatory syndrome in a rural area of Mozambique. PLoS One 6: e16946.
31. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M (2010) Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 10: 251–261.
32. Wei X, Deckler JM, Liu H, Zhang Z, Arani RH, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896–1905.
33. Mehta R, Bivalacqua-Mehla S, Zhang R, Hansly I, Albrecht H, et al. (2010) Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One 5: e11160.
34. Boesch-Saadatmandi C, Iloba A, Wagner AE, Stachurska A, Jozkowicz A, et al. (2011) Effect of quercetin and its metabolites isorhamnetin and quercetin-3-gluconate on inflammatory gene expression role of miR-155. J Nutr Biochem 22(3): 293–9.
35. Vijayakumar TS, Nath A, Chauhan A (2003) Chlorogenic mediated molecular tuning of astrocytes for enhanced permissiveness to HIV infection. Virology 315: 1–35.
46. Isel C, Karin J (1999) Direct evidence that HIV-1 Tat stimulates RNA polymerase II carboxyl-terminal domain hyperphosphorylation during transcriptional elongation. J Mol Biol 290: 929–941.
47. Kim YK, Bourgeois CF, Isel C, Churcher MJ, Karin J (2002) Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation. Mol Cell Biol 22: 4622–4637.
48. Zhang R, Mehta R, Chauhan A (2010) Perturbation of host nuclear membrane component RanBP2 impairs the nuclear import of human immunodeficiency virus -1 importin complex (DNA). PLoS One 5: e15620.
49. Yamamoto N, Tanaka C, Wu Y, Chang MO, Inagaki Y, et al. (2000) Analysis of human immunodeficiency virus type 1 integration by using a specific, sensitive and quantitative assay based on real-time polymerase chain reaction. Virus Genes 32: 105–113.
50. Mannioui A, Schiffer C, Felix N, Nelson E, Brussel A, et al. (2003) Cell cycle regulation of human immunodeficiency virus type 1 integration in T cells: antagonistic effects of nuclear envelope breakdown and chromatin condensation. Virology 329: 77–88.
51. Engelman A, Englund G, Orenstein JM, Martin MA, Craige R (1995) Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol 69: 2729–2736.
52. Chauhan A, Hahn S, Gartner S, Pardo CA, Netesan SK, et al. (2007) Molecular programming of endoplasmic reticulum in HIV-infected brain: role of Tat in up-regulation of ET-1 and its inhibition by statins. FASEB J 21: 777–789.
53. Chauhan A, Turchan J, Pocernich C, Bruce-Keller A, Roth S, et al. (2003) Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J Biol Chem 278: 13512–13519.
54. Desfosses Y, Solis M, Sun Q, Grandvaux N, Van Lim C, et al. (2005) Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins. J Virol 79: 9109–9119.
55. Kaneshita AJ, Kannangai R, Abraham OC, Pulimood SA, Sridharan G (2009) Amino acid sequence divergence of Tat protein (exon1) of subtype B and C HIV-1 strains: Does it have implications for vaccine development? Bioinformation 4: 257–241.
56. Kurou T, Mukai T, Komoto S, Brabham MS, Li YG, et al. (2002) Human immunodeficiency virus type 1 subtype C exhibits higher transcriptional activity of Tat than subtypes B and E. Microb Immunol 46: 787–799.
57. Chauhan A, Tikoo A, Kapur AK, Singh M (2007) The taming of the cell penetrating domain of the HIV Tat: myths and realities. J Control Release 117: 148–162.
58. Staub RH, Pavlakis GN (1998) Intracellular trafficking and interactions of the HIV-1 Tat protein. Virology 252: 126–136.
59. Weinberger LS, Burnet JE, Toeticher JE, Arkin AP, Schaffer DV (2005) Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 122: 169–182.
60. Baba M, Okamoto M, Kawamura M, Makino M, Higashiya T, et al. (1998) Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol Pharmacol 53(6): 1097–105.